Dubai, UAE, April 28th, 2026 - Symbiotic and Midas announced a joint offering designed to address one of the central frictions in tokenized asset markets: the lack of dependable, deep liquidity.
The offering, branded Symbiotic Instant Liquidity, is built on Symbiotic Core V2 and is integrated as an RFQ-based settlement layer within Midas' Open Liquidity Architecture. The product promises capital-efficient, onchain real-world-asset (RWA) redemptions that settle atomically - T+0 - without requiring market makers to maintain prefunded inventory or leaving capital idle between settlement events.
Most tokenized products have resolved access economics but still face structural illiquidity. According to the partners, redemptions for many tokenized assets can take between 60 and 180 days or longer, freezing investor capital until settlement processes conclude. Symbiotic Instant Liquidity is presented as a mechanism to remove that delay by converting committed capital into an enforceable, productive liquidity sleeve capable of instant settlement when a redemption is executed.
How it works in practice is simple in principle. An asset manager on the Midas platform initiates a redemption request. Symbiotic-registered market makers and curators then submit bids through an onchain request-for-quote (RFQ) system. The asset is priced, the best bid is selected, and the transfer plus settlement completes in a single onchain transaction. Market makers earn execution spread and do not need to pre-fund inventory to participate.
The same settlement path is designed to accommodate lending market liquidations via Redstone Settle, a process the partners identify as an historical bottleneck in DeFi systems that use tokenized assets. By enabling atomic settlement without large idle capital buffers, the RFQ layer aims to mitigate that constraint.
The technical enabler is Symbiotic Core V2. The upgrade introduces capital facilities that permit capital held in Symbiotic vaults to remain enforceable while being productively deployed between settlement events. Instead of sitting idle, committed funds may be allocated to whitelisted DeFi protocols such as Morpho and Euler and are configured to be automatically recalled when settlement obligations are triggered. That mechanism, according to the partners, allows redemptions to settle instantly without requiring market makers or issuers to hold pre-funded liquidity onchain.
Symbiotic and Midas name several participating and supporting parties in the ecosystem, including Keyring and Term Finance. The product will target most assets on Midas, with Fasanara's mGLOBAL fund cited as the first live asset to use the Symbiotic Instant Liquidity pathway after its tokenization on the Midas platform.
"Liquidity is what turns an asset class into a market. The RWA space has been building toward trillions without it. Symbiotic Core changes that: committed capital now functions as a liquidity sleeve, settling redemptions without sitting idle. This is what collateral markets infrastructure is built for." - Misha Putiatin, Co-Founder, Symbiotic
Midas recently raised $50 million in a Series A round to advance the development of institutional-grade tokenized financial products. The firm positions the RFQ settlement layer as an extension of its Open Liquidity Architecture, complementing existing instant redemption capabilities with a fully onchain, capital-efficient settlement pathway that is open to qualified market makers.
"The biggest friction point for tokenised products has always been redemptions. You can put a fund onchain, but if exiting still takes several weeks, you haven’t really solved anything. Symbiotic Instant Liquidity, as part of Midas’ Open Liquidity Architecture, changes that equation. On top of that, the capital backing redemptions is productive until the moment it’s needed, then settles atomically." - Dennis Dinkelmeyer, Co-Founder & CEO, Midas
Symbiotic describes Instant Liquidity as one product within a broader collateral markets ecosystem that already supports multiple financial verticals. Cap Labs is live in credit and Nexus Mutual is operating in insurance on the same infrastructure. The partners emphasize that the same base protocol can service different product types across different markets, and that any issuer can integrate while any market maker can participate, subject to qualification.
About Symbiotic: Symbiotic develops collateral markets where capital can be committed to contractual obligations while remaining productive. The architecture aims to remove the tradeoff between being locked and earning by allowing committed capital to back products in credit, insurance, stablecoins, and RWA. Symbiotic reports powering more than 80 vaults, over 74,000 active stakers, and 111 operators, with Chainlink, Nexus Mutual, and Cap Labs live in production. The company lists backing from Paradigm, Pantera, Cyber.fund, and Coinbase Ventures.
About Midas: Midas is a composable onchain investment product platform that helps strategy managers tokenize institutional strategies into "mTokens" that provide transparency, instant redemptions, and composability with DeFi protocols such as Morpho and Pendle. Founded in 2024 by Dennis Dinkelmeyer, Fabrice Grinda, and Romain Bourgois, the company counts investors including RRE, Creandum, Framework Ventures, HV Capital, Ledger, Cathay, and Coinbase Ventures. Midas says it recently closed a $50 million Series A and has supported over $1.7 billion in asset issuance and $37 million in yield paid out to date.
Contact for Symbiotic: Mia Adriaens - marketing@symbiotic.fi